Skip to main content
S 2157 115th Congress Senate Health

Drug-Price Transparency in Communications Act

Introduced: November 16, 2017 Introduced by: Durbin, Richard J. Democratic · Illinois See on congress.gov
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Nov 16, 2017
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Nov 16, 2017
Introduced in Senate
 Plain-English summary Congressional Research Service

Drug-Price Transparency in Communications Act

This bill amends the Federal Food, Drug, and Cosmetic Act to impose a civil penalty on any person who disseminates a direct-to-consumer drug advertisement that does not include the wholesale acquisition cost (the manufacturer's list price to wholesalers or direct purchasers) for a 30-day supply of the drug.

The bill requires any representative of a drug manufacturer who communicates with a health care practitioner about a drug manufactured by the drug manufacturer to disclose the wholesale acquisition cost for a 30-day supply of the drug.

What's happening now November 16, 2017

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

 Committees of jurisdiction 1